论文部分内容阅读
目的:探讨PECAM-1在肝细胞肝癌(Hepatocellular carcinoma,HCC)组织中的表达及意义。方法:选择2013年5月-2015年6月在我院接受治疗的HCC患者100例,收集肝癌患者HCC组织及癌旁组织,另选取100例正常肝脏组织作为对照组。应用免疫组织化学法检测PECAM-1在肝癌组织、癌旁组织以及正常肝脏组织中的阳性表达。利用小分子干扰RNA技术(si RNA)构建低表达的PECAM-1,并转染至肝癌细胞中抑制PECAM-1的表达。应用Transwell小室法检测肝癌细胞的侵袭能力,CCK-8法检测肝癌细胞的增殖能力。结果:PECAM-1在肝癌组织、癌旁组织及正常肝脏组织中呈不同程度阳性表达(P<0.05);PECAM-1在肝癌组织及癌旁组织中的表达显著高于正常肝脏组织,差异具有统计学意义(P<0.05);PECAM-1在肝癌组织中的表达显著高于癌旁组织,差异具有统计学意义(P<0.05);转染si RNA PECAM-1后,肝癌细胞中PECAM-1 m RNA的表达水平明显下降,PECAM-1蛋白表达也明显降低,差异具有统计学意义(P<0.05);转染si RNA PECAM-1后,肝癌细胞侵袭及增殖能力明显降低,差异具有统计学意义(P<0.001)。结论:PECAM-1在肝癌患者血清中高表达,PECAM-1 si RNA能够抑制肝癌细胞的侵袭及增殖能力,提示PECAM-1可作为预测肝癌发生及发展的临床指标。
Objective: To investigate the expression and significance of PECAM-1 in hepatocellular carcinoma (HCC). Methods: 100 cases of HCC patients treated in our hospital from May 2013 to June 2015 were selected. HCC tissues and paracancer tissues were collected from liver cancer patients. 100 normal liver tissues were selected as the control group. Immunohistochemistry was used to detect the positive expression of PECAM-1 in hepatocellular carcinoma tissues, paracancerous tissues and normal liver tissues. The low expression of PECAM-1 was constructed by using small interfering RNA (siRNA) technology and was transfected into hepatoma cells to inhibit the expression of PECAM-1. Transwell chamber assay was used to detect the invasion ability of hepatoma cells. CCK-8 assay was used to detect the proliferation of hepatoma cells. Results: The positive expression of PECAM-1 in hepatocellular carcinoma tissues, adjacent non-cancerous tissues and normal liver tissues was significantly different (P <0.05). The expression of PECAM-1 in hepatocellular carcinoma tissues and adjacent normal tissues was significantly higher than that in normal liver tissues (P <0.05). The expression of PECAM-1 in hepatocellular carcinoma was significantly higher than that in paracancerous tissues (P <0.05). After transfected with si RNA PECAM-1, the expression of PECAM- 1 m RNA expression decreased significantly, PECAM-1 protein expression also significantly reduced, the difference was statistically significant (P <0.05); transfected si RNA PECAM-1, hepatocellular carcinoma cell invasion and proliferation decreased significantly, the difference was statistically significant Significance (P <0.001). Conclusions: PECAM-1 is overexpressed in serum of hepatocellular carcinoma patients. PECAM-1 si RNA can inhibit the invasion and proliferation of hepatocellular carcinoma cells, suggesting that PECAM-1 can be used as a clinical marker to predict the occurrence and development of hepatocellular carcinoma.